Table 1.
Baseline Characteristics of Patients
| Variables | N = 33 |
|---|---|
| Male Sex | 25 (76) |
| Age (mean ± SD) | 62 ± 12 |
| PS (ECOG PS) | |
| 0–1 | 11 (33) |
| 2 | 11 (33) |
| 3–4 | 9 (27) |
| NA | 2 (7) |
| Histological subtype | |
| Adenocarcinoma | 24 (73) |
| Squamous cell carcinoma | 3 (9) |
| Other | 6 (18) |
| Gene alteration | |
| None | 18 (55) |
| EGFR | 1 (3) |
| ALK | 1 (3) |
| KRAS | 5 (16) |
| Other | 2 (6) |
| Cancer stage | |
| IIIB–C | 5 (15) |
| IV | 28 (85) |
| PD-L1, % | |
| ≥90 | 14 (42) |
| 50–89 | 15 (46) |
| 1–49 | 4 (12) |
| Charlson index (median, range) | 9 (6–15) |
| Complication motivating hospitalization (Main reason) | |
| Deterioration of general condition | 17 (52) |
| Acute respiratory failure | 6 (18) |
| Uncontrolled infection | 5 (15) |
| Uncontrolled bleeding | 3 (9) |
| Hypercalcemia | 1 (3) |
| Spinal cord compression | 1 (3) |
| Hospital unit | |
| Conventional care | 28 (85) |
| Intensive care | 5 (15) |
| Respiratory support | |
| None | 18 (55) |
| Conventional oxygen therapy | 9 (27) |
| High-flow nasal oxygen therapy | 5 (15) |
| Invasive ventilation | 1 (3) |
| Patient known to a palliative care team | 3 (9) |
| Long-term systemic corticotherapy ≥0 mg/day | 5 (15) |
| Antibiotics in the 2 months preceding the beginning of pembrolizumab | 20 (60) |
| Prior systemic treatments | 6 (18) |
| 1 single line of treatment | 5 (15) |
| 7 lines of treatment | 1 (3) |
| BMI (kg/m2) | |
| 18–25 | 12 (36) |
| 25–30 | 13 (40) |
| ≥30 | 4 (12) |
| NA | 4 (12) |
| Albumin (N = 35–45 g/liter), mean ± SD | 25.2 ± 7.5 |
| NLR, median (range) | 8.3 (0.3–150.5) |
Note: Values are given in n (%) unless indicated otherwise.
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; NA, not applicable; NLR, neutrophil-to-lymphocyte ratio; PD-L1, programmed death-ligand 1; PS, performance status.